12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
1 citations
,
March 2017 in “European Journal of Cancer Prevention” July 2025 in “Journal of Investigative Dermatology”
1 citations
,
September 2023 in “JAAD case reports” Mogamulizumab, a skin cancer drug, may cause hair loss similar to alopecia areata.
12 citations
,
March 2018 in “Medicine” A postmenopausal woman's hirsutism and high testosterone levels improved after surgery for an ovarian tumor not seen on ultrasound.
53 citations
,
November 2014 in “International Journal of Oncology” Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
6 citations
,
June 2006 in “International Journal of Gynecological Pathology” A postmenopausal woman's hormone imbalance and symptoms improved after removing benign ovarian tumors.
3 citations
,
June 2024 in “Frontiers in Endocrinology” COC treatment improves hormone and metabolic levels in PCOS patients.
May 2013 in “UTUPub (University of Turku)” Including androgens in hormone therapy may lower breast cancer risk.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
10 citations
,
May 2009 in “Cases Journal” A woman's masculine symptoms were caused by an ovarian tumor, which improved after surgery.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
August 2016 in “Journal of Investigative Dermatology”
April 2024 in “International journal of reproduction, contraception, obstetrics and gynecology” A 17-year-old girl was diagnosed with a rare ovarian tumor, emphasizing the need for fertility preservation and psychosocial care.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
April 2020 in “Journal of the Endocrine Society” A woman's high testosterone and related symptoms were caused by overactive cells in her ovaries.
12 citations
,
January 2018 in “Journal of Drug Delivery Science and Technology” The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.
April 2019 in “Journal of the Endocrine Society” A woman's severe insulin resistance improved with treatment, but she still had high testosterone levels due to ovarian issues.
November 2013 in “Cancer” Oophorectomy reduces ovarian cancer risk for women with BRCA mutations, finasteride lowers prostate cancer risk without raising death risk, and prophylactic mastectomy rates are rising.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for managing PCOS-related risks.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
August 2019 in “Repozitorij Farmaceutsko-biokemijskog fakulteta (Sveučilišta u Zagrebu)” PCOS treatment combines lifestyle changes and medication to manage symptoms and improve quality of life.
January 2011 in “Yearbook of Endocrinology”